Who
Charles J. Homcy
Director
Company insider
Files Form 4 as: Chairman of Pharmaceuticals, BridgeBio Pharma; Director, Maze Therapeutics; Director, Pliant Therapeutics; Director, Population Health Investment Co; Director and Other, Portola Pharmaceuticals; Director, Global Blood Therapeutics; Director, MyoKardia; Director, Cephalon.
In numbers
- Trades disclosed
- 285
- Buys
- 0
- Sells
- 36
- Bought
- $0
- Sold
- $51.9M
- Companies
- 12
- Companies where not an officer
- 11
- First trade
- 1 May 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 20 Jun 2026filed 23 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $52K788 at $66.27 | filing |
| 20 Jun 2026filed 23 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code F | $52K788 at $66.27 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code G | —7,422 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code G | —7,422 at $0.00 | filing |
| 19 Nov 2025filed 21 Nov 2025 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code J | —1,489 at $0.00 | filing |
| 23 Oct 2025filed 27 Oct 2025 | MAZE Maze TherapeuticsBiotechnology | SEC FORM 4 Code G | —28,423 at $0.00 | filing |
| 22 Sep 2025filed 24 Sep 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 11 Aug 2025filed 12 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $2.4M50,000 at $48.00 | filing |
| 8 Aug 2025filed 12 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $8.8M191,662 at $45.87 | filing |
| 8 Aug 2025filed 12 Aug 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $2.7M58,338 at $46.64 | filing |
| 27 Jun 2025filed 30 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code G | —20,000 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —6,589 at $0.00 | filing |
| 3 Feb 2025filed 4 Feb 2025 | MAZE Maze Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code C | —72,727 | filing |
News
No headline names them, or the companies they trade most, lately.